imatinib mesylate has been researched along with Eye Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hou, XY; Huang, M; Li, JL; Lin, CZ; Qiu, HB; Ruan, HL; Wang, XD; Wu, T; Xin, S; Zhou, ZW; Zhu, X; Zhuang, W | 1 |
| Abbasi, S; Alrabi, K; Awidi, A; Kheirallah, KA | 1 |
| Dogra, S; Handa, S; Khadwal, A; Kumari, S; Lad, D; Malhotra, P; Prakash, G; Suri, V; Varma, S; Vinay, K; Yanamandra, U | 1 |
| Dogan, SS; Esmaeli, B | 1 |
| Ho, WL; Wong, H; Yau, T | 1 |
| Druker, BJ; Esmaeli, B; Fraunfelder, FW; Kuyl, J; Solomon, J | 1 |
2 review(s) available for imatinib mesylate and Eye Diseases
| Article | Year |
|---|---|
Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor.
Topics: Benzamides; Eye Diseases; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Phosphorylcholine; Piperazines; Pyrimidines | 2009 |
The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Crizotinib; Erlotinib Hydrochloride; Eye Diseases; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Phosphorylcholine; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Trastuzumab | 2013 |
4 other study(ies) available for imatinib mesylate and Eye Diseases
| Article | Year |
|---|---|
Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1.
Topics: Alleles; ATP Binding Cassette Transporter, Subfamily B; ErbB Receptors; Eye Diseases; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Organic Cation Transporter 1; Polymorphism, Single Nucleotide; Solute Carrier Family 22 Member 5 | 2018 |
Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drugs, Generic; Eye Diseases; Female; Humans; Imatinib Mesylate; Jordan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nausea; Practice Patterns, Physicians'; Prospective Studies; Treatment Outcome; Young Adult | 2017 |
Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Cross-Sectional Studies; Drug Eruptions; Edema; Eye Diseases; Female; Humans; Hyperpigmentation; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Male; Middle Aged; Mouth Diseases; Mouth Mucosa; Nail Diseases; Sex Factors; Skin Diseases, Vesiculobullous; Time Factors; Young Adult | 2018 |
Ocular side-effects associated with imatinib mesylate (Gleevec).
Topics: Adult; Aged; Benzamides; Edema; Eye Diseases; Humans; Imatinib Mesylate; Lacrimal Apparatus Diseases; Male; Middle Aged; Piperazines; Pyrimidines; Time Factors; United States | 2003 |